Mesenchymal Stem Cell therapy - Medinno
Alternative Names: HIEstem™; MS-1901; MS-2001Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Medinno
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Brain hypoxia-ischaemia; Cerebral haemorrhage
Most Recent Events
- 07 Jan 2025 Mesenchymal Stem Cell therapy licensed to Cytonus Therapeutics in North America, Middle East and North Africa
- 07 Jan 2025 Phase-I clinical trials in Brain hypoxia-ischaemia in South Korea (Parenteral)
- 07 Jan 2025 Phase-I clinical trials in Cerebral haemorrhage in South Korea (Parenteral)